Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Christine Martinez

Physician Assistant, Surgical Walnut Creek, CA Physician Assistant

NPI 1871650523 CMS profile 10634713

2405 Shadelands Dr, Walnut Creek, CA 94598

Open in the dashboard

General payments

$1,788

31 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christine Martinez of Walnut Creek, CA is reported in the CMS Open Payments database as having received $1,788 across 31 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $623 11
2024 General $446 6
2023 General $106 4
2022 General $501 9
2021 General $111 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christine Martinez
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Christine Martinez were reported at $623. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Christine Martinez Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $111 $111 $36–$285 $132
2022 $501 $126 $44–$350 $149
2023 $106 $137 $47–$355 $160
2024 $446 $146 $49–$384 $164
2025 $623 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Zimmer Biomet Holdings, Inc. $299 3 payments
  2. Heron Therapeutics, Inc. $271 3 payments
  3. Bioventus LLC $208 4 payments
  4. Davol Inc. $171 2 payments
  5. Vertex Pharmaceuticals Incorporated $159 3 payments
  6. Pacira Pharmaceuticals Incorporated $140 1 payment
  7. Medical Device Business Services, Inc. $137 1 payment
  8. Ethicon US, LLC $104 1 payment
  9. Fidia Pharma USA Inc. $77 3 payments
  10. MY01 Inc. $44 2 payments
  11. Other $179 8 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,651 30 payments
  2. Education $137 1 payment
Products named General payments · program years 2021–2025
  1. DUROLANE $182 3 payments
  2. ZYNRELEF Post Surgical Pain Relief $160 2 payments
  3. JOURNAVX $159 3 payments
  4. Iovera $140 1 payment
  5. ROSA $117 2 payments
  6. Zynrelef Postoperative Pain $111 1 payment
  7. STRATAFIX $104 1 payment
  8. HYMOVIS $77 3 payments
  9. TRILURON $53 2 payments
  10. MY01 Continuous Compartmental Pressure Monitor $44 2 payments
  11. Other $212 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

826

Median for Physician Assistant: 241

Drug cost

$21,058

Median for Physician Assistant: $4,110

Branded share of claims

17.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 22 $7,669
Celecoxib Generic 195 $6,448
Naloxone Hcl Generic 55 $3,436
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 123 $1,227
Oxycodone Hcl Generic 152 $860
Cyclobenzaprine Hcl Generic 79 $681
Cephalexin Generic 113 $427
Tramadol Hcl Generic 33 $109
Omeprazole Generic 25 $82
Clindamycin Hcl Generic 17 $66

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$156,367

Of which drugs: $57,850

Medicare patients

638

Average age 75

Services billed

13,403

399 women, 239 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 70%
Ischemic heart disease 22%
Osteoporosis 21%
Chronic kidney disease 20%
Depression 20%
Atrial fibrillation 19%
Cancer 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 51 77 $30,894
Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg J7318 Office 52 4,320 $21,700
Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg J7328 Office 11 6,552 $2,661
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 106 737 $547

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

31 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Surgical in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record